RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
Mendler JH, Maharry K, Radmacher MD, Mrózek K, Becker H, Metzeler KH, Schwind S, Whitman SP, Khalife J, Kohlschmidt J, Nicolet D, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD.
Mendler JH, et al. Among authors: baer mr.
J Clin Oncol. 2012 Sep 1;30(25):3109-18. doi: 10.1200/JCO.2011.40.6652. Epub 2012 Jul 2.
J Clin Oncol. 2012.
PMID: 22753902
Free PMC article.
Clinical Trial.